Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma.
Aruni JhaMin H RyuOjo OoHilary J BewsJules C CarlsonJacquie SchwartzSujata BasuCharles S WongAndrew J HalaykoPublished in: British journal of pharmacology (2018)
Systemically administered simvastatin accumulates in the blood, but not in lung tissues, and reduces leukocyte influx and associated lung inflammation. Prophylactic therapy has the greatest anti-inflammatory effects, but as observed in human clinical trials, systemic simvastatin therapy does not prevent allergic airway hyperreactivity.
Keyphrases
- allergic rhinitis
- clinical trial
- endothelial cells
- oxidative stress
- gene expression
- chronic obstructive pulmonary disease
- randomized controlled trial
- lung function
- risk assessment
- induced pluripotent stem cells
- human health
- combination therapy
- cell therapy
- cystic fibrosis
- peripheral blood
- mesenchymal stem cells
- climate change
- study protocol
- smoking cessation
- polycyclic aromatic hydrocarbons